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Gadolinium Can Depict Area at Risk
and Myocardial Infarction
A Double-Edged Sword?*
Andrew E. Arai, MD
Bethesda, Marylandf
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tGadolinium-based extracellular contrast agents
have enabled cardiac magnetic resonance (CMR)
to assess viability and fibrosis at a higher resolu-
tion than alternative technologies (1). In this
issue of iJACC, Matsumoto et al. (2), present
convincing data that early contrast enhancement
approximately 2 min after administration of gad-
olinium depicts the area at risk associated with
acute myocardial infarction. The convenience of
imaging both the area at risk and the infarct size
from the same bolus of gadolinium appears to be
a huge convenience factor in expediting the
assessment of myocardial salvage, but this “2-
for-1” benefit is accompanied by the need to
understand the kinetics of gadolinium in the
infarct and the peri-infarct zone.
See page 610
Rather than concluding that gadolinium overes-
timates acute infarct size, the more appropriate and
challenging conclusion is that understanding the
kinetics of gadolinium contrast enhancement and
washout will help determine why gadolinium can
show both the penumbra of the area at risk and the
core of late gadolinium enhancement that repre-
sents the infarct. It will also be important to
understand a concept called the extracellular volume
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The pharmacological characteristics of the
adolinium contrast agents derive many of their
edical properties based on the chelates used to
ake the gadolinium biocompatible and excre-
able. Immediately after intravascular injection,
adolinium contrast agents are located in the
lasma of blood but excluded from the intracel-
ular space of blood cells. This point is important
or calibrating estimates of the intracellular volume
raction with measurement of the hematocrit. On
rrival in the coronary capillaries, gadolinium rap-
dly enters the extracellular space, but viable cardi-
myocytes exclude gadolinium from the intracellu-
ar space. The intracellular space represents
pproximately 75% of the normal myocardium,
hereas the extracellular space accounts for the
emaining 25% of the tissue volume, partly in the
orm of intramyocardial blood volume and partly as
nterstitial space. Acutely infarcted myocardium
ccumulates more gadolinium than remote myocar-
ium because ruptured cell membranes permit gad-
linium to access what had been the intracellular
pace. Thus, acutely infarcted myocardium gener-
lly looks brighter than viable myocardium on most
MR images unless microvascular obstruction pre-
ents entry of gadolinium into the tissue.
Understanding why gadolinium enhances the
rea at risk requires some interpretation and extrap-
lation from previous kinetic studies and observa-
ions from T2-weighted imaging of the area at risk.
n a careful study of 15 rats with reperfused 2-day-
ld infarcts imaged continuously for 40 min after
ontrast administration, Oshinski et al. (3) reported
hat gadolinium overestimated triphenyltetrazolium
hloride metrics of the infarct size for the first 16
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6202 min in rats that had 2-h occlusions and for 26 
4 min in the 30-min occlusion group. They con-
cluded that accurate determination of infarct size by
delayed enhancement CMR requires imaging at
specific times after gadolinium diethylenetriamine
pentaacetic acid injection, and this time varies with the
duration of occlusion. Those were contentious days in
the CMR scientific community because some experts
had concluded that gadolinium overestimated infarct
size (4,5). However, the remarkable improvement in
image quality of the new inversion recovery CMR
methods (6) and the extensive validations that came
ut in rapid succession (1,7–14) became an over-
helming tidal force that persuaded the CMR
eld and cardiology more generally that gadolin-
um was a new reference standard for viability
maging. However, based on the Oshinski et al.
3) data, our laboratory rigorously tried to per-
orm all acute infarct imaging approximately 20
in after gadolinium injection, which may ex-
lain why we believed that gadolinium reasonably
orrelated with acute infarct size (15).
So what has changed that the study by Matsu-
oto et al. (2) should change our understanding of
adolinium enhancement of the heart? Most im-
ortantly, Matsumoto et al. (2) noticed that early
adolinium enhancement (a.k.a. early contrast en-
ancement) overestimated infarct size but also took
he time to provide an independent metric of the
rea at risk—T2-weighted images. T2-weighted
mages have been validated to depict the area at risk
n animals (16,17) and in humans (18–21).
More importantly, the early gadolinium en-
ancement makes pharmacological sense based on
he T2 abnormalities in the area at risk and the
ssociated tissue swelling that must represent an
xpansion of the extracellular space (16–21). Inter-
stingly, Kim et al. (22) published kinetic data that
upport the existence of an expanded peri-infarct
xtracellular volume in addition to differing rates of
ash-in and washout of gadolinium from normal
yocardium, peri-infarct rim, and the infarct. Fig-amoto K, Shimada T, Mikuri M, mine infarct size achancement of the peri-infarct rim early during a
continuous infusion of gadolinium, and it is only
late during the washout phase that gadolinium-
related signal intensity of the infarct exceeded
normal myocardium or the peri-infarct rim (22).
Thus, there is substantial evidence from the litera-
ture to support the early gadolinium enhancement
findings of Matsumoto et al. (2), but they are to be
congratulated for noticing and proving with inde-
pendent methods that gadolinium enhances the
area at risk early after injection.
The take-home message from this lesson is that
gadolinium will overestimate the size of acute myo-
cardial infarctions in the first few minutes after
injection and appears to depict the area at risk
during that time period. More rapid clearance of
gadolinium from viable myocardium and more se-
vere abnormalities in the extracellular volume frac-
tion in the infarct will lead to a situation in which
the acutely infarcted myocardium is brighter than
either normal myocardium or salvaged myocardium
late after contrast injection. The optimal timing of
those 2 time periods will need to be defined more
precisely. For the short term, the best available data
(23) indicate that we should wait at least 10 min
after injection for accurate infarct sizing, but a
20-min wait would be safer still. More work is
needed to define the kinetics separating these 2
critical measurements such as renal function and
microvascular obstruction. That presents the
double-edged sword in the story: although it is
convenient to be able to measure 2 distinctly dif-
ferent physiologically relevant processes with a sin-
gle gadolinium injection, we will need to be careful
with our timing to avoid hybrid data between the
area at risk and infarct size.
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